Mar 16, 2026 Tirzepatide changed everything
Sources Novo Nordisk Wegovy HD (semaglutide 7.2 mg) FDA approval announcement, March 2026 The Lancet Diabetes & Endocrinology STEP UP trial: once-weekly semaglutide 7.2 mg in adults with obesity (2025) FDA Wegovy (semaglutide) prescribing information, 2025 PR Newswire FDA approves Wegovy HD injection (Novo Nordisk press release) NovoCare Wegovy cost and coverage information ClinicalTrials.gov STEP UP trial protocol (NCT05646706) New England Journal of Medicine STEP 1 trial: once-weekly semaglutide 2.4 mg Medical disclaimer This article is for informational purposes only and does not replace medical advice
(2008) reported that ingestion of a range of doses between 215 g of citrulline had no adverse effect on hematological markers (leucocytes, polymorphonuclears, lymphocytes, monocytes, erythrocytes, Hb) or biochemical markers (calcium, total proteins, albumin, C-reactive protein, urea, creatinine, glucose, cholesterol, triacylglycerol)
As the body adapts, these effects become more pronounced, and you may start noticing fewer cravings for high-calorie foods, leading to healthier eating habits